AIDS progress at risk as development aid cuts threaten gains

Approximately 1.2 million new HIV infections and 570,000 AIDS-related deaths recorded annually, with millions lacking access to preventive medicines in Sub-Saharan Africa and other regions.
Innovation without access is not innovation but injustice
UNAIDS director on why new preventive medicines mean nothing if people cannot afford them.
Mark

The report says infections are at a thirty-year low. That sounds like the story should be one of triumph. Why isn't it?

Mimi

Because the low number masks where the decline actually happened. Sub-Saharan Africa got the biggest decrease, but it still has half the world's new infections. And in three whole regions, infections went up. The victory is real but narrow.

Mark

So the medicines work, but people can't get them?

Mimi

Exactly. The preventive drugs exist. They work. But if you live in Sub-Saharan Africa or parts of the Middle East, the price is out of reach. Byanyima called it injustice dressed up as innovation.

Mark

And the funding is getting worse, not better?

Mimi

It dropped eighteen percent in one year. We're at the lowest funding level in nearly twenty years, right when we should be scaling up. It's a retreat at the moment of greatest capability.

Mark

Why would countries cut aid now?

Mimi

Budget pressures, shifting priorities, donor fatigue maybe. But the timing is brutal. The epidemic isn't over. It's just being managed in some places and left to spread in others.

Mark

What happens if the cuts continue?

Mimi

The gains reverse. The 1.2 million new infections, the 570,000 deaths—those numbers start climbing again. The fragile progress in Sub-Saharan Africa collapses first.

  • Global HIV infections have fallen to their lowest level in three decades, yet UNAIDS is sounding an alarm rather than a celebration — because the infrastructure sustaining that progress is being dismantled in real time.
  • International HIV prevention funding collapsed by eighteen percent in a single year, dropping to $7.3 billion, the lowest level in nearly two decades, as donor nations including Belgium quietly cut their development aid commitments.
  • The gains are dangerously uneven: three regions saw infection rates rise between 2010 and 2025, twenty-one countries moved in the wrong direction, and Sub-Saharan Africa still bears half of all new infections worldwide.
  • Preventive medicines that could dramatically reduce transmission exist but remain out of reach for millions in resource-limited regions — a gap that UNAIDS director-general Winnie Byanyima calls not a medical failure but an act of injustice.
  • Without a reversal in funding commitments, the progress announced in Rio risks becoming a historical high-water mark rather than a foundation for the epidemic's end.

At a global AIDS conference in Rio de Janeiro, humanity finds itself at a peculiar crossroads: the tools to end a decades-long epidemic exist, the knowledge has been hard-won, and yet the collective will to sustain the effort is quietly withdrawing. UNAIDS reports that new HIV infections have reached their lowest point in thirty years, a testament to what sustained international commitment can achieve — but a simultaneous eighteen-percent drop in prevention funding threatens to unravel that achievement before it becomes permanent. The story of AIDS in 2025 is not one of failure, but of a hard-earned victory being placed, almost casually, at risk.

Rio de Janeiro is hosting the International AIDS Conference this week, and the moment is as tense as it is significant. UNAIDS has released a progress report that tells two stories at once: one of genuine, hard-won achievement, and one of a gathering threat that could erase it.

By 2025, the world will record approximately 1.2 million new HIV infections — the lowest annual count in thirty years — and 570,000 AIDS-related deaths, also a three-decade low. These numbers reflect decades of treatment expansion, prevention campaigns, and sustained international commitment. But UNAIDS is careful not to let the headline figures obscure a more complicated reality.

The decline is not evenly shared. Eastern Europe and Central Asia, Latin America, and the Middle East and North Africa have all seen infection rates rise since 2010. Twenty-one countries are moving in the wrong direction. Sub-Saharan Africa, despite recording the largest regional decrease, still accounts for half of all new HIV cases globally. Progress, where it exists, is concentrated in places where resources have flowed most reliably.

Access remains the defining problem. Preventive medicines that could dramatically reduce transmission risk exist, but millions in Sub-Saharan Africa and other resource-limited regions cannot afford them. UNAIDS director-general Winnie Byanyima put the contradiction plainly: innovation without access is not progress but injustice.

The funding picture explains much of this gap. International HIV prevention support dropped eighteen percent in a single year — from $8.8 billion to $7.3 billion — reaching its lowest level in nearly two decades. Belgium is among the donor nations that have cut official development assistance, adding to the pressure at precisely the moment the epidemic remains far from controlled.

The paradox is stark: the world knows how to prevent and treat HIV better than ever, yet the political will to fund that knowledge at scale is contracting. The gains of thirty years are real, but they rest on a foundation that is visibly cracking.

Rio de Janeiro is hosting the International AIDS Conference this week, and the timing could not be more fraught. UNAIDS, the United Nations agency tracking the global HIV epidemic, has released its latest progress report—and it tells a story of genuine achievement shadowed by a gathering threat.

The numbers on the surface look like a victory. By 2025, the world will have recorded approximately 1.2 million new HIV infections, the lowest annual count in three decades. Deaths from AIDS-related illness have fallen to 570,000, also the lowest in thirty years. These are real gains, the product of decades of treatment expansion, prevention campaigns, and sustained international commitment. But UNAIDS is careful not to let the headline numbers obscure what lies beneath them.

The decline in infections is not evenly distributed across the globe. Three regions—Eastern Europe and Central Asia, Latin America, and the Middle East and North Africa—have actually seen infection rates rise between 2010 and 2025. Twenty-one countries have moved in the wrong direction entirely. Sub-Saharan Africa, despite recording the largest regional decrease in new infections, still accounts for half of all new HIV cases worldwide. The progress that exists is fragile, concentrated in places where resources have flowed most reliably, and absent in others.

Access remains the central problem. New preventive medicines exist that could dramatically reduce transmission risk, but millions of people in Sub-Saharan Africa and other resource-limited regions cannot obtain them at any price they can afford. Winnie Byanyima, the director-general of UNAIDS, framed the contradiction plainly: innovation without access is not progress but injustice. The measure of success, she said, is not whether medicines exist but whether the people who need them can actually get them.

The funding picture explains much of this gap. International support for HIV prevention dropped eighteen percent in the past year alone, falling from 8.8 billion dollars to 7.3 billion. This represents the lowest level of international funding for HIV prevention in nearly two decades—a reversal at precisely the moment when the epidemic remains far from controlled. Belgium, among other donor nations, has cut its official development assistance budgets, adding to the pressure.

The paradox is stark: the world has learned how to prevent and treat HIV more effectively than ever before, yet the political will to fund that knowledge at scale is contracting. The gains of the past three decades are real, but they rest on a foundation that is visibly cracking. Without a reversal in funding commitments, UNAIDS is warning that the progress documented in Rio will not hold. The next phase of the fight against AIDS will be defined not by what medicine can do, but by what the world is willing to pay for.

Innovation without access is not innovation but injustice. The measure of success is not whether medicines exist, but whether the people who need them can access them at an affordable price.
— Winnie Byanyima, Director-General of UNAIDS
Contact Us FAQ